STOCK TITAN

Akebia Therapeutics (AKBA) grants RSUs and stock options to director Rogers

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Akebia Therapeutics, Inc. reported that director Michael W. Rogers received new equity awards. He acquired 35,700 shares of common stock in the form of restricted stock units granted at no cash cost and not yet vested. He also received a stock option for 53,600 shares of common stock with an exercise price of $1.02 per share. Both the RSUs and the option vest in full on the first anniversary of the June 17, 2026 grant date, or immediately before the first annual stockholder meeting after that date, if earlier, subject to his continuous service. Following these awards, he directly holds 197,429 shares of common stock and 53,600 stock options.

Positive

  • None.

Negative

  • None.
Insider ROGERS MICHAEL W
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to buy) 53,600 $0.00 --
Grant/Award Common Stock 35,700 $0.00 --
Holdings After Transaction: Stock Option (Right to buy) — 53,600 shares (Direct, null); Common Stock — 197,429 shares (Direct, null)
Footnotes (1)
  1. The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date. The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
RSUs granted 35,700 shares Restricted stock units granted to director on June 17, 2026
Stock option granted 53,600 shares Option to buy common stock granted to director
Option exercise price $1.02 per share Exercise price of newly granted stock option
Shares held after grant 197,429 shares Common stock directly owned following RSU grant
Option vesting 100% after one year Stock option vests in full on first anniversary or earlier annual meeting
RSU vesting 100% after one year RSUs vest in full on first anniversary or earlier annual meeting
restricted stock units financial
"The restricted stock units (the "RSUs") were granted by the Issuer"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2023 Stock Incentive Plan financial
"were granted by the Issuer pursuant to its 2023 Stock Incentive Plan"
Non-Employee Director Compensation Program financial
"as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program"
Stock Option financial
"The option to purchase shares of the Issuer's common stock (the "Stock Option")"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
continuous service financial
"subject to the Reporting Person's continuous service to the Issuer through such vesting date"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What equity awards did Akebia Therapeutics (AKBA) director Michael W. Rogers receive?

Michael W. Rogers received 35,700 restricted stock units and a stock option for 53,600 shares. The option has a $1.02 exercise price and both awards were granted under Akebia’s 2023 Stock Incentive Plan and its non-employee director compensation program.

When do Michael W. Rogers’ new Akebia (AKBA) RSUs and options vest?

Both the 35,700 RSUs and the 53,600-share stock option vest 100% on the first anniversary of the June 17, 2026 grant date. Vesting can occur earlier, immediately before the first annual stockholder meeting after grant, if he remains in continuous service.

What is the exercise price of Michael W. Rogers’ new Akebia (AKBA) stock option?

The new stock option granted to Michael W. Rogers has an exercise price of $1.02 per share. It covers 53,600 shares of Akebia common stock and becomes fully exercisable upon vesting under the company’s 2023 Stock Incentive Plan framework.

How many Akebia (AKBA) shares does Michael W. Rogers hold after these grants?

After the equity grants, Michael W. Rogers directly holds 197,429 shares of Akebia common stock. He also holds a newly granted option for 53,600 additional shares, which will be exercisable once it vests according to the plan’s vesting schedule.

Under which plan were Michael W. Rogers’ Akebia (AKBA) awards granted?

The RSUs and stock option were granted under Akebia’s 2023 Stock Incentive Plan. They were provided pursuant to the company’s Fifth Amended and Restated Non-Employee Director Compensation Program, which governs equity compensation for outside board members.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ROGERS MICHAEL W

(Last)(First)(Middle)
C/O AKEBIA THERAPEUTICS, INC.
245 FIRST ST.

(Street)
CAMBRIDGE MASSACHUSETTS 02142

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Akebia Therapeutics, Inc. [ AKBA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/17/2026A35,700(1)A$0.00197,429D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to buy)$1.0206/17/2026A53,60006/17/2027(2)06/17/2036Common Stock53,600$0.0053,600D
Explanation of Responses:
1. The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
2. The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Remarks:
/s / Carolyn Rucci, attorney-in-fact for Michael W. Rogers06/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)